Rosetta Biosoftware announced today that Oji Paper Co., Ltd. in Tokyo, Japan licensed the Rosetta Resolver® system to characterize gene expression profiles of wood forming tissues. The Resolver system will be used in the Forestry Research Institute, which uses biotechnology applications to investigate which tree species are suitable for afforestation and paper manufacturing material.

"The Resolver system will further enhance and enrich our data analysis," said Takashi Hibino, Ph.D., research scientist at the Forestry Research Institute, Oji Paper Co., Ltd. "We are collecting gene-expression profiles of elite trees during cell elongation and wood formation to understand gene regulation in wood-forming tissues. The differences between these expression profiles could be identified as potential biomarkers for high-quality fibers for paper production, which can be effective for silviculture and breeding."

?At Rosetta Biosoftware, we take pride in developing a robust data management and statistical analysis platform to support biotechnology research,? said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "The Resolver system is designed to be a versatile, scalable framework for gene expression analysis for any biotechnology application, in addition to drug discovery applications. We are pleased to provide the Resolver system to Oji Paper to support its research in silviculture and enhance its rate of discovery.?

About Oji Paper Co., Ltd.

Oji Paper Co., Ltd. is a leading Japanese paper and end-use product supplier. It is involved in the conversion/processing and sales of a wide variety of paper products including; printing and writing paper, packaging and wrapping papers, carbonless papers, household products, containerboard and boxboard. It produces and sells end-use products such as corrugated board and boxboard containers, paper-board containers, plastics, thermal paper, self-adhesive paper and disposable paper diapers, as well as the chemicals for paper-making and packaging equipment. It maintains company-owned forests and is involved in reforestation efforts both in Japan and overseas.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Sanofi-Aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.